Session 1 - Future of migraine management

Hashmat Ghanizada

MD and PhD Fellow, Danish Headache Center, Rigshospitalet, Glostrup, Denmark

CGRP is one of a family of peptides which share varying degrees of affinity with their receptors. Treatments to prevent migraine are not effective in all patients; this may be due to the effects of other calcitonin peptides in the trigeminal ganglion, including amylin and adrenomedullin.

References
1. Hay DL, Garelja ML, Poyner DR, Walker CS. Update on the pharmacology of calcitonin/ CGRP family of peptides: IUPHAR Review 25. Br J Pharmacol. 2018;175:3-17.
2. Garelja ML, Au M, Brimble MA, et al. Molecular mechanisms of Class B GPCR activation: insights from adrenomedullin receptors. ACS Pharmacol Transl Sci. 2020;3:246-262.
3. Edvinsson L, Grell AS, Warfvinge K. Expression of the CGRP family of neuropeptides and their receptors in the trigeminal ganglion. J Mol Neurosci. 2020;70:930-944.
4. Walker CS, Eftekhari S, Bower RL, et al. A second trigeminal CGRP receptor: function and expression of the AMY1 receptor. Ann Clin Transl Neurol. 2015;2:595-608.
5. Ashina M, Hansen JM, Á Dunga BO, et al. Human models of migraine - short-term pain for long-term gain. Nat Rev Neurol. 2017;13:713-724.
6. Charles A, Pozo-Rosich P. Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet. 2019;394:1765-1774.